Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

Learn more about:
Related Clinical Trial
A Phase 1, Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas AMG 319 Lymphoid Malignancy FIH Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Tandem Auto-Allo Transplant for Lymphoma Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas CD4CAR for CD4+ Leukemia and Lymphoma Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma A Study for Patients With Non-Hodgkin’s Lymphomas High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Allo-HSCT as First-line Consolidation in High-risk PTCL A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low ( T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Gemcitabine in NK/T Cell Lymphoma A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma Trial of Endostar Combined With CHOPT for T Cell Lymphoma Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Brief Title

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

Official Title

A Phase 2b Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

Brief Summary

      Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy
      of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL)

Detailed Description

      This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and
      efficacy of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL). HBI
      8000 will be administered orally approximately 30 minutes after any regular meal twice a
      week. There will be 3 to 4 days between dosing. A treatment cycle is defined as 28
      consecutive days. HBI-8000 administration will be continued until disease progression or
      unacceptable toxicities are observed despite appropriate dose reduction or treatment

Study Phase

Phase 2

Study Type


Primary Outcome

Objective Response Rate

Secondary Outcome

 Objective Response Rate by disease subtype


Adult T-Cell Lymphoma (ATL)



Study Arms / Comparison Groups

Description:  Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 2016

Completion Date

November 2019

Primary Completion Date

December 2018

Eligibility Criteria

        Inclusion Criteria:

          1. Histopathological, or cytological diagnosis of ATL confirmed as seropositive for
             anti-Human T-lymphotrophic Virus type-I (HTLV-I) antibody

          2. Acute, lymphoma or unfavorable chronic types. The unfavorable chronic type is defined
             by the presence of at least 1 of the following: serum albumin <3.5 g/dL, lactic
             dehydrogenase (LDH) >300 U/L, or blood urea nitrogen (BUN) >25 mg/dL. The patient must
             have at least 1 of measurable lesion, or evaluable lesion in either of peripheral
             blood or skin

          3. Relapsed or refractory disease after receiving prior systemic therapy with
             mogamulizumab, or ≥1 prior systemic therapy with cytotoxic chemotherapy in case of
             intolerance/contraindication for mogamulizumab. And there is no other available
             treatment which can be considered appropriate for patients

          4. Male or female, aged 20 years or older

          5. ECOG Performance Status of 0-2

          6. Life expectancy of greater than 3 months

          7. Meeting the following laboratory criteria for screening:

               -  Absolute Neutrophil Count >1500/µL independent of growth factor support within 7
                  days of starting the study drug

               -  Platelets >75,000/µL independent of transfusion within 14 days of starting the
                  study drug

               -  Hgb >8 g/dL independent of transfusion within 14 days of starting the study drug

               -  Serum creatinine < upper limit of normal (ULN)

               -  Serum aspartate aminotransferase/glutamyl oxaloacetic transaminase (AST/SGOT) and
                  alanine aminotransferase/glutamyl pyruvic transaminase (ALT/SGPT) less than or
                  equal to 3 X ULN

               -  Serum Bilirubin less than or equal to 1.5 X ULN

          8. Negative serum pregnancy test for females of childbearing (reproductive) potential.
             Female patients of child bearing potential must use an effective method of birth
             control (e.g., hormonal contraceptive, intrauterine device, diaphragm with spermicide
             or condom with spermicide) during treatment period and 1 month thereafter; Males must
             use an effective method of birth control (2 barrier methods) during treatment period
             and 3 months thereafter.

             Note: Female patients will be considered to be women of childbearing potential unless
             having undergone permanent contraception or postmenopausal. Postmenopausal is defined
             as at least 12 months without menses with no other medical reasons (e.g., chemical
             menopause because of treatment with anti-malignant tumor agents).

          9. Signed informed consent

        Exclusion Criteria:

        2.5.2 Exclusion Criteria:

          1. Patients in whom central nervous system lymphoma is recognized during screening (if
             suspected clinically, imaging study should be performed to confirm)

          2. Male patients with QTcF > 450 msec at screening, female patients with QTcF > 470 msec
             at screening, or patients with congenital long QT syndrome, clinically significant
             arrhythmia, history of congestive heart failure (New York Heart Association Class III
             or IV) or acute myocardial infarction within 6 months of starting the study drug at

          3. Patients with known hypersensitivity to benzamide class of compounds or any of the
             components of HBI-8000 tablets, and patients with prior exposure of HBI-8000;

          4. Patients with a history of second malignancy other than disease under study. The
             exceptions are disease that has been treated with curative intent with no evidence of
             recurrence in past 2 years including:

               -  Basal cell carcinoma of the skin

               -  Squamous cell carcinoma of the skin

               -  Cervical carcinoma in situ

               -  Carcinoma in situ of the breast

               -  An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b)

               -  Early-stage gastric cancer treated with endoscopic mucosal resection or
                  endoscopic submucosal dissection

          5. Autologous stem cell transplantation within 12 weeks (84 days) of starting the study

          6. History of allogeneic stem cell transplantation

          7. Organ transplantation recipients except autologous hematopoietic stem cell

          8. Uncontrolled inter-current infection

          9. Hepatitis B surface antigen-positive, or hepatitis C virus antibody positive. In case
             hepatitis B core antibody and/or hepatitis B surface antibody is positive even if
             hepatitis B surface antigen negative, a hepatitis B virus DNA test (real-time PCR
             measurement) should be performed and if positive, the patient should be excluded from

         10. Any history of testing positive for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency syndrome (AIDS)

         11. Uncontrolled diabetes mellitus, hypertension, endocrine disorder, bleeding disorder

         12. Major surgery or radiation therapy within 28 days of starting the study drug

         13. Receiving investigational agents or anti-cancer therapy within 28 days, nitrosourea or
             mitomycin C within 42 days, of starting the study drug

         14. Receiving antibody therapy for ATL within 12 weeks of starting the study drug

         15. Women who are breastfeeding or women who are not willing to stop breastfeeding during
             study treatment period and for 30 days after the last dose of study drug

         16. Potential for non-compliance or at increased risk based on investigator's judgement




20 Years - N/A

Accepts Healthy Volunteers



Gloria Lee, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

HUYABIO International, LLC.


 Quintiles, Inc.

Study Sponsor

Gloria Lee, MD, Study Chair, HUYA Bioscience International, LLC

Verification Date

October 2020